Fractyl Health, Inc. - Common Stock - Bilanço (NASDAQ:GUTS)

Financials

Toplam varlıklar 108.08 M121.4 M Toplam yükümlülükler 79.65 M111.94 M Toplam özsermaye 28.42 M9.46 M Toplam yükümlülükler ve hissedarların özsermayesi 108.08 M121.4 M Toplam borç 30.16 M30.59 M Net borç -37.3 M-50.95 M

Fractyl Health, Inc. - Common Stock

Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.

GUTS

Financials

Fractyl Health, Inc. - Common Stock

Haberler

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health diyabet gen terapisi denemesi için onay aldı

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health 4Ç 2025: Maliyetler düştü, hisse geriledi

Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fractyl Health: Low Market Expectations Create Trading Opportunity With 2026 Catalysts

Morgan Stanley, Revita denemesi sonuçları nedeniyle Fractyl Health hisse senedi notunu düşürdü

Morgan Stanley downgrades Fractyl Health stock rating to Equalweight on Revita trial results

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11%

Why Is Fractyl Health Stock Tumbling Today? - Fractyl Health (NASDAQ:GUTS)

Fractyl Health hisseleri GLP-1 kilo koruma verileri sonrası düştü